Highbridge Capital Management’s AbbVie ABBV Stock Holding History

Highbridge Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,000	Closed	-$279K	–	468
2018 Q2	$279K	Buy	+3,000	New	+$293K	0.01%	724
2018 Q1	–	Sell	-25,800	Closed	-$2.5M	–	1131
2017 Q4	$2.5M	Buy	25,800 +14,600	+130%	+$1.38M	0.04%	353
2017 Q3	$994K	Buy	11,200 +8,000	+250%	+$609K	0.01%	598
2017 Q2	$233K	Sell	3,200 -7,800	-71%	-$524K	﹤0.01%	1058
2017 Q1	$717K	Sell	11,000 -9,300	-46%	-$585K	0.01%	745
2016 Q4	$1.27M	Buy	20,300 +10,200	+101%	+$623K	0.02%	483
2016 Q3	$638K	Buy	+10,100	New	+$654K	0.01%	693
2016 Q1	–	Sell	-23,100	Closed	-$1.37M	–	1435
2015 Q4	$1.37M	Buy	+23,100	New	+$1.33M	0.02%	641
2015 Q3	–	Sell	-6,900	Closed	-$464K	–	1480
2015 Q2	$464K	Sell	6,900 -9,500	-58%	-$620K	0.01%	1000
2015 Q1	$960K	Buy	+16,400	New	+$991K	0.01%	765

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Highbridge Capital Management's ABBV Position: Q3 2018 in Review

Highbridge Capital Management sold out of AbbVie (ABBV) in Q3 2018, closing a stake of 71,495 shares — an estimated $6.62M sold.

Highbridge Capital Management first reported a position in ABBV in Q2 2013 and held it in 17 quarters. The position peaked at $71.2M in Q1 2015. 1,957 funds tracked by Wall St. Rank hold ABBV as of Q3 2018.

Highbridge Capital Management reported no remaining AbbVie position as of Q3 2018 after selling out during the quarter.
Highbridge Capital Management sold 71,495 AbbVie shares in Q3 2018, an estimated $6.62M.
Highbridge Capital Management first reported a position in AbbVie in Q2 2013 and held it in 17 quarters.
Highbridge Capital Management's AbbVie position peaked at $71.2M in Q1 2015.
1,957 funds tracked by Wall St. Rank held AbbVie as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.